PIK3CA and neoplasm: Nevertheless, in two phase II studies of mTORC1 inhibitors, PIK3CA and PTEN mutations in EC tumours could not predict patient outcome [112,116], but this could be due to the use of an agent targeting just a single kinase (as explained above).